Glecaprevir/Pibrentasvir — Discount Pricing

Other medications in Infectious Disease

• Levofloxacin
• Molnupiravir
• Nirmatrelvir/Ritonavir
• Nitrofurantoin
• Sofosbuvir/Velpatasvir
• Trimethoprim
• Amoxicillin
• Azithromycin

What Glecaprevir/Pibrentasvir is approved for (FDA label)

MAVYRET is indicated for the treatment of adult and pediatric patients 3 years and older with acute or chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5 or 6 infection without cirrhosis or with compensated cirrhosis (Child-Pugh A).

Source: Read the full FDA label on DailyMed. Label effective date: June 25, 2025.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Boxed warning for Glecaprevir/Pibrentasvir (FDA label)

WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with MAVYRET. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated [see Warnings and Precautions ( 5.1 )] . WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN PATIENTS COINFECTED WITH HCV AND HBV See full prescribing information for complete boxed warning. Hepatitis B virus (HBV) reactivation has been reported, in some cases resulting in fulminant hepatitis, hepatic failure, and death. ( 5.1 )

Source: FDA prescribing information (DailyMed). Set ID: 7bf99777-0401-9095-8645-16c6e907fcc0. SPL document ID: c1aa97e0-7350-4286-ac17-915bcdf0b08a. Label effective date: June 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Glecaprevir/Pibrentasvir (FDA label)

MAVYRET is available as tablets or pellets for oral use. Tablets: pink, oblong-shaped, film-coated, and debossed with “NXT” on one side. Each tablet contains 100 mg glecaprevir and 40 mg of pibrentasvir. Oral pellets: pink and yellow coated pellets in unit-dose packets. Each packet contains 50 mg glecaprevir and 20 mg pibrentasvir. Tablets: 100 mg glecaprevir and 40 mg pibrentasvir. ( 3 ) Oral Pellets: 50 mg glecaprevir and 20 mg pibrentasvir. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 7bf99777-0401-9095-8645-16c6e907fcc0. SPL document ID: c1aa97e0-7350-4286-ac17-915bcdf0b08a. Label effective date: June 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Glecaprevir/Pibrentasvir (FDA label)

In subjects receiving MAVYRET, the most commonly reported adverse reactions (greater than 10%) are headache and fatigue. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of MAVYRET cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Overall Adverse Reactions in Subjects with Chronic HCV Infection without Cirrhosis or with Compensated Cirrhosis (Child-Pugh A) The adverse reactions data for MAVYRET in subjects without cirrhosis or with compensated cirrhosis (Child-Pugh A) were derived from nine registrational Phase 2 and 3 trials which evaluated approximately 2,300 adults infected with genotype 1, 2, 3, 4, 5, or 6 HCV who received MAVYRET for 8, 12 or 16 weeks [see Clinical Studies ( 14 ) ] . The overall proportion of subjects who permanently discontinued treatment due to adverse reactions was 0.1% for subjects who received MAVYRET for 8, 12 or 16 weeks. The most common adverse reactions, all grades, observed in greater than or equal to 5% of subjects receiving 8, 12, or 16 weeks of treatment with MAVYRET were headache (13%), fatigue (11%), and nausea (8%).

Source: FDA prescribing information (DailyMed). Set ID: 7bf99777-0401-9095-8645-16c6e907fcc0. SPL document ID: c1aa97e0-7350-4286-ac17-915bcdf0b08a. Label effective date: June 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Glecaprevir/Pibrentasvir (FDA label)

MAVYRET is contraindicated in patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation [see Warnings and Precautions ( 5.2 ), Use in Specific Populations ( 8.7 ) and Clinical Pharmacology ( 12.3 )] . MAVYRET is contraindicated with atazanavir or rifampin [see Drug Interaction ( 7.3 ) and Clinical Pharmacology ( 12.3 )] . Patients with moderate or severe hepatic impairment (Child-Pugh B or C) or those with any history of prior hepatic decompensation. ( 4 , 5.2 ) Coadministration with atazanavir or rifampin. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 7bf99777-0401-9095-8645-16c6e907fcc0. SPL document ID: c1aa97e0-7350-4286-ac17-915bcdf0b08a. Label effective date: June 25, 2025. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.